Helio Genomics receives 2024 innovation award from California Investment Forum
Helio Genomics has been honored by the California Investment Forum (CIF) for its innovations in utilizing AI-based technology in developing its HelioLiver test for early liver cancer detection.
Helio was presented with a 2024 Innovation Award for AI-Based Medical Technology as applied to its HelioLiver. HelioLiver is a multi-analyte blood test that analyzes cell-free DNA (cfDNA), methylation patterns, serum protein markers and demographic information with a simple blood draw to detect hepatocellular carcinoma, or HCC, the most common form of liver cancer.
Criteria for the award included:
· Innovation
· Impact
· Practicality and Scalability
· Market Performance
· Academic and Clinical Validation
· Industry Recognition
